Treatment with angiotensin-converting enzyme inhibitors, angiotensin
II receptor blockers, and β-adrenoreceptor antagonists are strongly associated
with reduced morbidity and mortality from heart failure, but whether patients
at highest risk of adverse outcomes are prescribed these agents is not clear.
Lee and colleagues evaluated administration rates for these medications at
hospital discharge and for 90 days after discharge in 9942 patients predicted
to be at low, intermediate, and high risk of death from heart failure within
1 year. They found an inverse relationship between prescription rates and
predicted and observed risks of death in patients with heart failure.